# Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

> **NCT01431690** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 52 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** warfarin
- **DRUG:** omefas
- **DRUG:** omega-3-acid ethyl esters

## Key facts

- **NCT ID:** NCT01431690
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431690, "Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01431690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*